You're contacting media contact of this press release

Title: Andarix Pharmaceuticals to Present Theranostic Clinical Data for ¹⁸⁸Re-P2045 Tozaride at TAT 13 International Symposium

Andarix Pharmaceuticals, a leader in the discovery and development of targeted radiopharmaceutical therapy for cancer, announced today that it will present a poster at the 13th International Symposium of Targeted Alpha Therapy (TAT 13), held jointly with the 19th Edwaldo Camargo Symposium on Beta Therapy. The conference will take place April 14–16, 2026, at the Windsor Barra Convention Center in Rio de Janeiro, Brazil. The poster, titled "Theranostic Clinical Study with ¹⁸⁸Re P2045 in Lung Cancer Expressing SSTR and Well-Differentiated Neuroendocrine Tumors," presents clinical data from the Company’s lead radiopharmaceutical asset, Tozaride (¹⁸⁸Re-AX-188 / ¹⁸⁸Re-P2045), across studies evaluating its theranostic potential in somatostatin receptor (SSTR)-positive malignancies. The abstract has been accepted for publication in the Annals of the Journal of Medical Imaging and Radiation Sciences (JMIRS) as part of the TAT 13 proceedings. Tozaride is a proprietary somatostatin peptide conjugate radiolabeled with Rhenium-188, a beta-emitting radioisotope that also enables imaging, making it a true theranostic agent. The presentation will highlight data from the Company’s clinical program encompassing 75 patients across four studies, underscoring Tozaride’s potential in lung cancer and neuroendocrine tumor indications where somatostatin receptors are highly upregulated. “We are excited to share our clinical theranostic data with the global radiopharmaceutical community at this prestigious symposium,” said Chris Adams, Founder and CEO of Andarix Pharmaceuticals. “TAT 13 represents an ideal forum for presenting the Tozaride program, and we look forward to engaging with leading experts in targeted radionuclide therapy as we advance this asset toward broader clinical...

This press release is issued by King Newswire